- Home
- TLSA vs BYSI Comparison
TLSA vs BYSI Comparison
Compare TLSA & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- BYSI
- Stock Information
- Founded
- TLSA 2013
- BYSI 2010
- Country
- TLSA United Kingdom
- BYSI United States
- Employees
- TLSA N/A
- BYSI N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- BYSI Health Care
- Exchange
- TLSA Nasdaq
- BYSI Nasdaq
- Market Cap
- TLSA 87.8M
- BYSI 72.1M
- IPO Year
- TLSA 2000
- BYSI 2017
- Fundamental
- Price
- TLSA $1.07
- BYSI $1.31
- Analyst Decision
- TLSA
- BYSI
- Analyst Count
- TLSA 0
- BYSI 0
- Target Price
- TLSA N/A
- BYSI N/A
- AVG Volume (30 Days)
- TLSA 363.4K
- BYSI 24.5K
- Earning Date
- TLSA 05-09-2025
- BYSI 01-01-0001
- Dividend Yield
- TLSA N/A
- BYSI N/A
- EPS Growth
- TLSA N/A
- BYSI N/A
- EPS
- TLSA N/A
- BYSI N/A
- Revenue
- TLSA N/A
- BYSI N/A
- Revenue This Year
- TLSA N/A
- BYSI N/A
- Revenue Next Year
- TLSA N/A
- BYSI N/A
- P/E Ratio
- TLSA N/A
- BYSI N/A
- Revenue Growth
- TLSA N/A
- BYSI N/A
- 52 Week Low
- TLSA $0.49
- BYSI $0.98
- 52 Week High
- TLSA $1.91
- BYSI $3.63
- Technical
- Relative Strength Index (RSI)
- TLSA 53.21
- BYSI 44.17
- Support Level
- TLSA $0.76
- BYSI $1.03
- Resistance Level
- TLSA $1.13
- BYSI $1.27
- Average True Range (ATR)
- TLSA 0.11
- BYSI 0.15
- MACD
- TLSA -0.00
- BYSI 0.00
- Stochastic Oscillator
- TLSA 85.00
- BYSI 48.53
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.